Moleculin's MIRACLE Trial: 37% Blinded CRc in Venetoclax-Failed AML, Enrollment Nearly Complete
MBRX is trading near its 52-week low of $1.01 (15% above the low) on elevated volume (2.9× avg).
Summary
Moleculin's MIRACLE trial reported 37% blinded CRc in 62 evaluable R/R AML patients, with identical rates in the venetoclax-failure subgroup — roughly 3x published salvage remission rates. Enrollment is nearing completion, with unblinded data expected around year-end.
Updates
· Wiseek News — The $9.3M unit offering priced at $0.75 closes today with 12.38M shares and up to 37.13M warrants.
Key Events · Product Development and Regulatory · MBRX
-
Updated Blinded Efficacy Data
Preliminary blinded CR rate of 24% and CRc rate of 37% in 62 evaluable patients. In the 30-patient venetoclax-failure subgroup, CR was 23% and CRc 37% — essentially identical to the overall population and roughly 3x the published salvage remission rate of ~13%.
-
Enrollment Progress and Timeline
Enrollment reached 74 of 90 patients. Final Part A treatment expected in September 2026, with comprehensive unblinded Part A results on track for the December 2026 – February 2027 timeframe.
-
Continued Cardiac Safety
No evidence of cardiotoxicity observed, reinforcing Annamycin's differentiation from conventional anthracyclines.
-
Financing Context
The update follows a July 29 S-1 filing to raise up to $10 million; the company has a going-concern warning and needs significant additional capital to complete the trial.
Analysis · MBRX · Life Sciences
Moleculin reported updated blinded data from its pivotal Phase 2/3 MIRACLE trial, showing a 37% composite complete remission rate (CRc) in 62 evaluable patients — including a 37% CRc in the 30 patients who had failed prior venetoclax therapy, a subgroup with historically poor outcomes (published salvage remission rates ~13%, median survival ~2.4 months). The consistency of remission rates across the overall and venetoclax-failure populations, combined with continued absence of cardiotoxicity, strengthens the case for Annamycin's differentiated profile. With enrollment at 74 of 90 patients and final Part A treatment expected in September 2026, the company is on track for unblinded comprehensive data in the December 2026 – February 2027 window. This update comes just two days after an S-1 filing to raise up to $10 million, highlighting the critical need for capital to reach these milestones. The data incrementally de-risks the program and could support partnering or regulatory discussions, but the company's going-concern warning and thin cash position remain significant overhangs.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $1.01 to $18.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.